Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Drug Development (5)
683 Articles Available
5
29
Can't find what you're looking for? Try our
advanced search
.
Immunotherapy
Leveraging the Native Immune Response to Fight Cancer
PAP-Q2-20-CL-017
Novel Antibiotics
Applying a Synthetic Approach to the Development of a New Generation of Antibiotics
PAP-Q2-20-CL-019
In Conversation
In Conversation: Novel Off-The-Shelf Targeted Cell Therapies
PAP-Q2-20-CL-021
Epigenetics
Epigenetic Regulation to Treat Acute Organ Injury and Chronic Liver Diseases
PAP-Q2-20-CL-022
Endocrine Diseases
Developing Transformative Treatments for Rare Endocrine Diseases
PAP-Q2-20-CL-023
Cancer and Neurodegenerative Diseases
Leveraging the Cell Cytoskeleton for the Treatment of Cancer and Neurodegenerative Diseases
PAP-Q2-20-CL-024
Coping with COVID-19
COVID-19: Understanding the Virus, the Pandemic, and the Path Forward
PAP-Q2-20-NI-004
Roundtable
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
PAP-Q2-20-RT-002
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
PR-M06-20-NI-020
COVID-19
Low-cost Dexamethasone Reduces Death in Patients with Severe Respiratory Complications of COVID-19
PR-M06-20-NI-018
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
PR-M06-20-NI-017
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
PR-M06-20-NI-019
HIV
ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP
PR-M05-20-NI-034
Innovation
HKBU Scientists Eliminate Drug Side Effects by Manipulating Molecular Chirality
PR-M05-20-NI-029
Cancer Treatment
HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment
PR-M05-20-NI-024
Clinical Trials
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 Clinical Trial for the Treatment of Obstructive Hypertrophic Cardiomyopathy
PR-M05-20-NI-021
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
PR-M05-20-NI-018
COVID-19 Treatment
Pneumagen Ltd Announces Positive Anti-Viral Activity for Novel Glycan Approach in Preventing Coronavirus Infections
PR-M04-20-NI-038
M&A
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
PR-M04-20-NI-036
FDA Approval
Seattle Genetics Announces FDA Approval of TUKYSA for Breast Cancer
PR-M04-20-NI-028
Biosimilar
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
PR-M04-20-NI-014
COVID-19
COVID-19: A Look at the Virus, its Epidemiology, Therapeutic and Vaccine Development Efforts and Impacts of the Pandemic
PAO-Q2-20-NI-001
Drug Development
A New Approach for Diseases Associated with BH4-Dependent Enzymatic Pathways
PAP-Q1-20-CL-011
In Conversation
In Conversation: NantKwest — Harnessing Natural Killer Cells to Treat Cancer
PAP-Q1-20-CL-016
«
5
29
»
.svg)